Über das Unternehmen
- Firmenname (rechtlich): Autotelic Bio
- Registrierungsland: Republic of Korea
- Adresse: Osongsaengmyeong 1-ro, Heungdeok-gu
- Anzahl der Mitarbeiter: 25 - 49
Beschreibung:
Autotelic Bio researches and develops innovative new drugs with a vision of becoming a global leader in cancer treatment, driven to improve quality of life for patients with unmet medical needs. Founded in 2015 with board members bringing 15-20 years of experience across pharmaceutical business development, R&D and clinical study, the company's lead candidate ATB-301 (a TGF-β2-targeting antisense oligonucleotide combined with IL-2 therapy) is in Phase Ib trials, exploring TGF-β2 as a biomarker, suppression of IL-2 side effects in combination therapy, and the synergistic effects and safety of the combination approach.
Geschäftsaktivitäten
ATC-Klassifikation (Anatomisch-Therapeutisch-Chemisch)
Hersteller
Hauptprodukte/-dienstleistungen
- :
- :
- :
Bewertungen
(0)
(0)
(0)
(0)
(0)
Kommentare
Filter:
Sortieren nach:
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen